GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets multiple cancers in patients out of options
Disease control Not yet recruitingThis is a first-in-human study to find a safe dose and understand how the body processes an experimental oral drug called ACC-1898. The drug aims to block proteins that help cancer cells grow and spread. The study will enroll about 40 adults with advanced solid tumors who have ru…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Direct tumor injections aim to boost chemo power against stomach cancer
Disease control Not yet recruitingThis study is testing whether injecting an experimental treatment called RP2 directly into stomach or esophagus tumors, along with standard chemotherapy (FLOT), is safe and works better than chemotherapy alone before surgery. Researchers want to see if this combination kills more…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New Three-Drug attack on stomach cancer tested in surgery patients
Disease control Not yet recruitingThis study is testing whether adding a new drug called IBI343 to a standard treatment helps people with advanced stomach or gastroesophageal cancer. The goal is to shrink the tumor before surgery and prevent it from coming back afterward. It is for patients whose tumors have a sp…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for tough stomach cancers: testing a powerful drug duo
Disease control Not yet recruitingThis study is testing a new combination of two immunotherapy drugs (Iparomlimab/Tuvonralimab) with a chemotherapy drug for people with advanced stomach or gastroesophageal junction cancer. It's for patients whose cancer has continued to grow or who couldn't tolerate their first s…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: Qingxia Li • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC